Rectal Cancer

Oncology·MeSH: Rectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

284 drugs in development·74 companies·19 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
alymsys	Amneal Pharmaceuticals, Inc. (AMRX)
Cyramza	ELI LILLY & Co (LLY)
Cyramza®	ELI LILLY & Co (LLY)
Erbitux	ELI LILLY & Co (LLY)
Erbitux®	ELI LILLY & Co (LLY)
krazati	BRISTOL MYERS SQUIBB CO (BMY)
leucovorin calcium preservative free	Seagen Inc. (SGEN)
leucovorin calcium preservative free	Mylan II B.V. (MYL)
vykoura	Kaya Holdings, Inc. (KAYS)
zaltrap	Sanofi (SNY)

Phase 3(72)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
amivantamab	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
Amivantamab + FOLFIRI	IGM Biosciences, Inc. (IGMS)
amivantamab iv	GH Research PLC (GHRS)
Avelumab	IGM Biosciences, Inc. (IGMS)
Biweekly FOLFIRI	IGM Biosciences, Inc. (IGMS)
blood intake	Cidara Therapeutics, Inc. (CDTX)
Calcium folinate	IGM Biosciences, Inc. (IGMS)
Calcium levofolinate	IGM Biosciences, Inc. (IGMS)
CAPOX	IGM Biosciences, Inc. (IGMS)
Cetuximab	Merus N.V. (MRUS)
Cetuximab	KYNTRA BIO INC. (KYNB)
Cetuximab	ENANTA PHARMACEUTICALS INC (ENTA)
Cetuximab	BRISTOL MYERS SQUIBB CO (BMY)
Chemotherapy	IGM Biosciences, Inc. (IGMS)
Chemotherapy Regimen 1	BioNTech SE (BNTX)
Chemotherapy Regimen 2	BioNTech SE (BNTX)
CMAB009	IGM Biosciences, Inc. (IGMS)
Drug	Summit Therapeutics Inc. (SMMT)
FOLFIRI	Amneal Pharmaceuticals, Inc. (AMRX)
FOLFIRI Protocol	IGM Biosciences, Inc. (IGMS)
folfiri regimen	Mirati Therapeutics, Inc. (MRTX)
folfiri regimen	AMGEN INC (AMGN)
FOLFIRI regimen	IGM Biosciences, Inc. (IGMS)
FOLFIRI+cetuximab	IGM Biosciences, Inc. (IGMS)
folfox	GH Research PLC (GHRS)
folfox	Incyte Corp. (INCY)
FOLFOX	KYNTRA BIO INC. (KYNB)
FOLFOX	Amneal Pharmaceuticals, Inc. (AMRX)
FOLFOX	IGM Biosciences, Inc. (IGMS)
FOLFOX-4	IGM Biosciences, Inc. (IGMS)
FOLFOX-7	IGM Biosciences, Inc. (IGMS)
FOLFOX+QL1706+Cetuximab	KYNTRA BIO INC. (KYNB)
Fruquintinib Combined With Chemotherapy	IGM Biosciences, Inc. (IGMS)
fruquintinib+chemotherapy	IGM Biosciences, Inc. (IGMS)
gevokizumab	NOVARTIS AG (NVSEF)
IBI351, cetuximab β combined with FOLFIRI	IGM Biosciences, Inc. (IGMS)
inca33890	Incyte Corp. (INCY)
l-leucovorin	Merus N.V. (MRUS)
leucovorin	GH Research PLC (GHRS)
Leucovorin	BRISTOL MYERS SQUIBB CO (BMY)
Leucovorin/levofolinate calcium	Merus N.V. (MRUS)
mFOLFOX6	IGM Biosciences, Inc. (IGMS)
mfolfox6 regimen	Mirati Therapeutics, Inc. (MRTX)
mFOLFOXIRI	IGM Biosciences, Inc. (IGMS)
Modified FOLFOX-6 regimen	Merus N.V. (MRUS)
Molecular analysis of exon 9 and 20 of PI3K	Cidara Therapeutics, Inc. (CDTX)
nis793	Novartis AG (NVS)
Panitumumab	IGM Biosciences, Inc. (IGMS)
Panitumumbab	IGM Biosciences, Inc. (IGMS)
PD-1 Monoclonal Antibody	IGM Biosciences, Inc. (IGMS)
Postoperative reintroduction of FOLFIRI based chemotherapy	IGM Biosciences, Inc. (IGMS)
regorafenib	IGM Biosciences, Inc. (IGMS)
rmc-6236	REVOLUTION MEDICINES, INC. (RVMD)
rmc-9805	REVOLUTION MEDICINES, INC. (RVMD)
Serplulimab	KYNTRA BIO INC. (KYNB)
Sintilimab	IGM Biosciences, Inc. (IGMS)
Standard Chemotherapy	BioNTech SE (BNTX)
standard second-line chemotherapy	IGM Biosciences, Inc. (IGMS)
Standard systemic therapy	IGM Biosciences, Inc. (IGMS)
Systemic therapy	IGM Biosciences, Inc. (IGMS)
tak-113	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-113	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
TAS-102	Merus N.V. (MRUS)
Tiragolumab	IGM Biosciences, Inc. (IGMS)
tislelizumab	BeOne Medicines Ltd. (ONC)
Tislelizumab	BeOne Medicines Ltd. (ONC)
tremelimumab	CG Oncology, Inc. (CGON)
trifluridine/tipiracil	AbbVie Inc. (ABBV)
Young TIL	Filana Therapeutics Inc. (FLNA)

Phase 2(88)

Drug	Company
350 mg leronlimab	CytoDyn Inc. (CYDY)
5-fu	NuCana plc (NCNA)
700 mg leronlimab	CytoDyn Inc. (CYDY)
AK112	IGM Biosciences, Inc. (IGMS)
AK119	IGM Biosciences, Inc. (IGMS)
Aldesleukin	Filana Therapeutics Inc. (FLNA)
Amivantamab	IGM Biosciences, Inc. (IGMS)
Amivantamab IV	IGM Biosciences, Inc. (IGMS)
Avutometinib	ENANTA PHARMACEUTICALS INC (ENTA)
Biweekly FOLFIRI	REGENXBIO Inc. (RGNX)
Biweekly FOLFIRI	KYNTRA BIO INC. (KYNB)
Biweekly FOLFIRI	Merus N.V. (MRUS)
Biweekly Modified FOLFOX6	Merus N.V. (MRUS)
Biweekly Modified FOLFOX6	KYNTRA BIO INC. (KYNB)
Biweekly Modified FOLFOX6	IGM Biosciences, Inc. (IGMS)
Biweekly Modified FOLFOX6	REGENXBIO Inc. (RGNX)
BMS-986340	ENANTA PHARMACEUTICALS INC (ENTA)
cabozantinib	NOVARTIS AG (NVSEF)
CAPOX	Merus N.V. (MRUS)
Cediranib	ASTRAZENECA PLC (AZN)
cetuximab	PFIZER INC (PFE)
CTX-009	Compass Therapeutics, Inc. (CMPX)
Defactinib	ENANTA PHARMACEUTICALS INC (ENTA)
denikitug	GILEAD SCIENCES, INC. (GILD)
Eliglustat+Immune checkpoint inhibitor	Crinetics Pharmaceuticals, Inc. (CRNX)
Eliglustat+Immune checkpoint inhibitor +Regorafenib	Crinetics Pharmaceuticals, Inc. (CRNX)
Elraglusib Oral Tablet	ACTUATE THERAPEUTICS, INC. (ACTU)
Emavusertib	ADMA BIOLOGICS, INC. (ADMA)
FLOX	Merus N.V. (MRUS)
FLOX	ENANTA PHARMACEUTICALS INC (ENTA)
Floxuridine	BridgeBio Oncology Therapeutics, Inc. (BBOT)
Floxuridine	Merus N.V. (MRUS)
folfiri	ASTRAZENECA PLC (AZN)
folfiri	ONCOLYTICS BIOTECH INC (ONCY)
folfiri	Cardiff Oncology, Inc. (CRDF)
folfiri	Novartis AG (NVS)
folfiri	Novartis AG (NVS)
FOLFIRI regimen	REGENXBIO Inc. (RGNX)
folfox	Cardiff Oncology, Inc. (CRDF)
FOLFOX	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFOX regimen	KYNTRA BIO INC. (KYNB)
FOLFOX regimen	Arcus Biosciences, Inc. (RCUS)
FOLFOX regimen	IGM Biosciences, Inc. (IGMS)
folinic acid	AbbVie Inc. (ABBV)
Fosifloxuridine Nafalbenamide	IGM Biosciences, Inc. (IGMS)
Hydroxychloroquine	IGM Biosciences, Inc. (IGMS)
Inavolisib	IGM Biosciences, Inc. (IGMS)
Iparomlimab and Tuvonralimab	IGM Biosciences, Inc. (IGMS)
leucovorin	KYNTRA BIO INC. (KYNB)
Leucovorin	AbbVie Inc. (ABBV)
Leucovorin	Jazz Pharmaceuticals plc (JAZZ)
mFOLFOX6	KYNTRA BIO INC. (KYNB)
mFOLFOXIRI	KYNTRA BIO INC. (KYNB)
mFOLFOXIRI	Merus N.V. (MRUS)
mFOLFOXIRI	REGENXBIO Inc. (RGNX)
modified folfox6	Novartis AG (NVS)
modified folfox6	Novartis AG (NVS)
navicixizumab	OncoMed Pharmaceuticals Inc (OMED)
ngm120 q4w	NGM BIOPHARMACEUTICALS INC (NGM)
ngm120 q8w	NGM BIOPHARMACEUTICALS INC (NGM)
NK Cells	FATE THERAPEUTICS INC (FATE)
Olaparib	Merus N.V. (MRUS)
ompenaclid	IGM Biosciences, Inc. (IGMS)
Ompenaclid	Crinetics Pharmaceuticals, Inc. (CRNX)
Ompenaclid	Merus N.V. (MRUS)
Ompenaclid	REGENXBIO Inc. (RGNX)
Ompenaclid	ENANTA PHARMACEUTICALS INC (ENTA)
onvansertib	Cardiff Oncology, Inc. (CRDF)
Onvansertib	IGM Biosciences, Inc. (IGMS)
Onvansertib (Onv)	Cardiff Oncology, Inc. (CRDF)
ozekibart	Inhibrx Biosciences, Inc. (INBX)
panitumumab	AbbVie Inc. (ABBV)
Panitumumab	Merus N.V. (MRUS)
PDS01ADC	BridgeBio Oncology Therapeutics, Inc. (BBOT)
PDS01ADC	IGM Biosciences, Inc. (IGMS)
pelareorep	ONCOLYTICS BIOTECH INC (ONCY)
PM8002	BioNTech SE (BNTX)
Regorafenib	MACROGENICS INC (MGNX)
Regorafenib+Immune checkpoint inhibitor	Crinetics Pharmaceuticals, Inc. (CRNX)
ro7198457	BioNTech SE (BNTX)
RO7198457 intravenous	BioNTech SE (BNTX)
sirexatamab	CYPHERPUNK TECHNOLOGIES INC. (CYPH)
TAS-102	AIM ImmunoTech Inc. (AIM)
tislelizumab	Novartis AG (NVS)
Trifluridine + Tipiracil	ENANTA PHARMACEUTICALS INC (ENTA)
trifluridine-tipiracil	GILEAD SCIENCES, INC. (GILD)
Vincristine Sulfate Liposome	ENANTA PHARMACEUTICALS INC (ENTA)
ZN-c3	Zentalis Pharmaceuticals, Inc. (ZNTL)

Phase 1(53)

Drug	Company
AB680	Arcus Biosciences, Inc. (RCUS)
Adagrasib	IGM Biosciences, Inc. (IGMS)
Balstilimab	UNITED THERAPEUTICS Corp (UTHR)
BET Bromodomain Inhibitor ZEN-3694	Amneal Pharmaceuticals, Inc. (AMRX)
BNT314	BioNTech SE (BNTX)
Botensilimab	UNITED THERAPEUTICS Corp (UTHR)
cabozantinib	Novartis AG (NVS)
Cetuximab	Zentalis Pharmaceuticals, Inc. (ZNTL)
Chemotherapy	Syndax Pharmaceuticals Inc (SNDX)
Divarasib	IGM Biosciences, Inc. (IGMS)
Emavusertib	Merus N.V. (MRUS)
Emavusertib	BridgeBio Oncology Therapeutics, Inc. (BBOT)
Emavusertib	ENANTA PHARMACEUTICALS INC (ENTA)
Encorafenib	ENANTA PHARMACEUTICALS INC (ENTA)
Encorafenib	Zentalis Pharmaceuticals, Inc. (ZNTL)
Epacadostat	Merus N.V. (MRUS)
Fludarabine	Amneal Pharmaceuticals, Inc. (AMRX)
FOLFIRI	BridgeBio Oncology Therapeutics, Inc. (BBOT)
FOLFIRI	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFIRI	REGENXBIO Inc. (RGNX)
FOLFOX	REGENXBIO Inc. (RGNX)
FOLFOX	BridgeBio Oncology Therapeutics, Inc. (BBOT)
gevokizumab	Novartis AG (NVS)
hro761	Novartis AG (NVS)
hro761	NOVARTIS AG (NVSEF)
im-1617	Immunome Inc. (IMNM)
IMC-R117C (PIWIL-1)	Immunocore Holdings plc (IMCR)
intrathecal chemotherapy	Syndax Pharmaceuticals Inc (SNDX)
JAB-21822	IGM Biosciences, Inc. (IGMS)
JNJ-89402638	Merus N.V. (MRUS)
JNJ-89402638	IGM Biosciences, Inc. (IGMS)
JNJ-89402638	BridgeBio Oncology Therapeutics, Inc. (BBOT)
JNJ-89402638	ENANTA PHARMACEUTICALS INC (ENTA)
JNJ-89402638	REGENXBIO Inc. (RGNX)
KRAS Vaccine with Poly-ICLC adjuvant	UNITED THERAPEUTICS Corp (UTHR)
Leucovorin Calcium	CURIS INC (CRIS)
Leucovorin Calcium	ADMA BIOLOGICS, INC. (ADMA)
LPM6690176	IGM Biosciences, Inc. (IGMS)
me-344	Lite Strategy, Inc. (LITS)
mFOLFOX6	BridgeBio Oncology Therapeutics, Inc. (BBOT)
mrtx849	Mirati Therapeutics, Inc. (MRTX)
panitumumab	AMGEN INC (AMGN)
ProAgio	IGM Biosciences, Inc. (IGMS)
promitil	Rafael Holdings, Inc. (RFL)
Pumitamig	Merus N.V. (MRUS)
ramucirumab	NOVARTIS AG (NVSEF)
ramucirumab	Novartis AG (NVS)
Regorafenib	ENANTA PHARMACEUTICALS INC (ENTA)
Revumenib	Syndax Pharmaceuticals Inc (SNDX)
RP3	Replimune Group, Inc. (REPL)
SY-5609	IGM Biosciences, Inc. (IGMS)
tagmokitug	Coherus Oncology, Inc. (CHRS)
varsetatug masetecan	CytomX Therapeutics, Inc. (CTMX)

Preclinical(6)

Drug	Company
imx-111	Immix Biopharma, Inc. (IMMX)
KRAS program	Cogent Biosciences, Inc. (COGT)
mink-215	MiNK Therapeutics, Inc. (INKT)
Pan-mutant BRAF degrader program (proprietary)	Nurix Therapeutics, Inc. (NRIX)
Pan-mutant BRAF program (mutant BRAF degraders)	Nurix Therapeutics, Inc. (NRIX)
RCC-33	CNBX Pharmaceuticals Inc. (CNBX)

Unknown(4)

Drug	Company
HSV1 viral therapeutic platform	Bullfrog AI Holdings Inc. (BFRG)
mfolfox6 + panitumumab combination therapy	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
mfolfox6 + panitumumab combination therapy	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
shield	Guardant Health Inc. (GH)

Early Phase 1(10)

Drug	Company
Encorafenib	Amneal Pharmaceuticals, Inc. (AMRX)
experimental	VERTEX PHARMACEUTICALS INC / MA (VRTX)
Panitumumab	Amneal Pharmaceuticals, Inc. (AMRX)
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine	IGM Biosciences, Inc. (IGMS)
Sotorasib	IGM Biosciences, Inc. (IGMS)
Sotorasib	Amneal Pharmaceuticals, Inc. (AMRX)
Trifluridine/tipiracil	IGM Biosciences, Inc. (IGMS)
Trifluridine/tipiracil	Amneal Pharmaceuticals, Inc. (AMRX)
Tucatinib	Amneal Pharmaceuticals, Inc. (AMRX)
Tucatinib	IGM Biosciences, Inc. (IGMS)

N/A(2)

Drug	Company
N-Acetyl Cysteine	Merus N.V. (MRUS)
Vitamin D	Cidara Therapeutics, Inc. (CDTX)

Phase 1/Phase 2(21)

Drug	Company
cetuximab	REVOLUTION MEDICINES, INC. (RVMD)
cetuximab	Mirati Therapeutics, Inc. (MRTX)
fosifloxuridine nafalbenamide	NuCana plc (NCNA)
gcc19cart	Lyell Immunopharma, Inc. (LYEL)
imc-r117c	Immunocore Holdings plc (IMCR)
leucovorin	NuCana plc (NCNA)
lyl273	Lyell Immunopharma, Inc. (LYEL)
m-FOLFOX-6 regimen	Arcus Biosciences, Inc. (RCUS)
mfolfirinox regimen	REVOLUTION MEDICINES, INC. (RVMD)
mfolfox6 regimen	REVOLUTION MEDICINES, INC. (RVMD)
nuc-3373	NuCana plc (NCNA)
nuc-3373 + leucovorin	NuCana plc (NCNA)
nufiri	NuCana plc (NCNA)
nufiri + egfr inhibitor	NuCana plc (NCNA)
nufiri + vegf pathway inhibitor	NuCana plc (NCNA)
nufox	NuCana plc (NCNA)
nufox + egfr inhibitor	NuCana plc (NCNA)
nufox + vegf pathway inhibitor	NuCana plc (NCNA)
REC-617	RECURSION PHARMACEUTICALS, INC. (RXRX)
Regorafenib	Arcus Biosciences, Inc. (RCUS)
son-1210	SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG)

Phase 2/Phase 3(6)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)
CAPOX	BRISTOL MYERS SQUIBB CO (BMY)
FOLFIRI	BRISTOL MYERS SQUIBB CO (BMY)
FOLFOX	BRISTOL MYERS SQUIBB CO (BMY)
granite	Gritstone bio, Inc. (GRTS)
tovecimig (CTX-009)	Compass Therapeutics, Inc. (CMPX)

Phase 4(12)

Drug	Company
5-Flurouracil	Merus N.V. (MRUS)
5-FU	IGM Biosciences, Inc. (IGMS)
BMS-813160	BRISTOL MYERS SQUIBB CO (BMY)
Cetuximab	IGM Biosciences, Inc. (IGMS)
Cetuximab	Filana Therapeutics Inc. (FLNA)
Cetuximab wkly	IGM Biosciences, Inc. (IGMS)
Folinic acid	IGM Biosciences, Inc. (IGMS)
Leucovorin	IGM Biosciences, Inc. (IGMS)
Leucovorin and 5-FU	IGM Biosciences, Inc. (IGMS)
Neoadjuvant olaparib	ASTRAZENECA PLC (AZN)
NG-350A IV administration	Merus N.V. (MRUS)
Olaparib	ASTRAZENECA PLC (AZN)

Compare drugs

alymsys vs Cyramza alymsys vs Erbitux alymsys vs krazati

Frequently asked questions

How many drugs are in development for Rectal Cancer?

BioSniper tracks 284 drugs in development for Rectal Cancer across 74 companies.

How many clinical trials target Rectal Cancer?

There are 19 clinical trials targeting Rectal Cancer tracked by BioSniper.

What is the prevalence of Rectal Cancer?

The estimated prevalence of Rectal Cancer is approximately 135.0 per 100,000 population.

Deep-dive into Rectal Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis